<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961348</url>
  </required_header>
  <id_info>
    <org_study_id>U-2015-341</org_study_id>
    <secondary_id>2015-00881</secondary_id>
    <nct_id>NCT02961348</nct_id>
  </id_info>
  <brief_title>TIMING of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation</brief_title>
  <official_title>Timing of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation: a Prospective Multicenter Registry-based Non-inferiority Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Swedish Stroke Register (Riksstroke)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare early with late start of treatment with Non-vitamin K oral&#xD;
      anticoagulation (NOAC) in adult patients with acute ischemic stroke and atrial fibrillation;&#xD;
      it is a registry-based randomized clinical trial (R-RCT) using The Swedish Stroke Register&#xD;
      (Riksstroke). Half of the patients will start NOAC early (within 4 days after stroke onset)&#xD;
      while the other half will start late (5-10 days after stroke onset).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Oral anticoagulation therapy is well established and highly recommended for the prevention of&#xD;
      recurrent ischemic stroke in patients with atrial fibrillation, but the optimal time point to&#xD;
      start after an acute ischemic stroke is not known.&#xD;
&#xD;
      The intervention in this study will be timing of treatment onset. The choice of NOAC (i.e.&#xD;
      apixaban, dabigatran, edoxaban or rivaroxaban) after the acute ischemic stroke is at the&#xD;
      discretion of the treating physician.&#xD;
&#xD;
      This study will use the Swedish Stroke Register for enrolment, randomization and follow-up,&#xD;
      with additional data linkage from other mandatory national registers. Primary outcome will be&#xD;
      assessed at 90 days and secondary outcomes (including all-cause mortality and health economic&#xD;
      analyses) and will be assessed at 90 days and up to one year after the index ischemic stroke.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 15, 2017</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Actual">June 10, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite outcome of recurrent ischemic stroke, symptomatic intracerebral hemorrhage, or all-cause mortality</measure>
    <time_frame>90 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent acute ischemic stroke</measure>
    <time_frame>90 days</time_frame>
    <description>Defined as a new focal neurological deficit of sudden onset lasting at least 24 h (or &lt;24 h if following therapeutic intervention, i.e. thrombolysis or thrombectomy, or if the deficit results in death &lt; 24 h), occurring &gt;24 hours after the index ischemic stroke, irrespective of vascular territory and that is not attributable to edema, brain shift, hemorrhagic transformation, intercurrent illness, hypoxia, or drug toxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic intracerebral hemorrhage (S-ICH)</measure>
    <time_frame>90 days</time_frame>
    <description>Defined as a new focal neurological deficit of sudden onset lasting at least 24 h with documented intracerebral hemorrhage (ICH) on imaging (computed tomography (CT) or magnetic resonance imaging (MRI)). Any intraparenchymal hematoma (≥10mm) will be considered, including hemorrhagic transformation of the index ischemic stroke. However microhemorrhages (&lt;10mm) are not considered to be an ICH. ICH will be classified as symptomatic if it is associated with ≥4 points in total NIHSS or ≥2 points in one NIHSS category</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>90 days</time_frame>
    <description>Defined by grade on the modified Rankin Scale (mRS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major hemorrhages</measure>
    <time_frame>90 days</time_frame>
    <description>Defined as bleedings that are fatal or life-threatening (according to the definition by the International Society on Thrombosis and Haemostasis) or lead to hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">888</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Early start of NOAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day 1 to day 4 after ischemic stroke onset</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Late start of NOAC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Day 5 to day 10 after ischemic stroke onset</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Early start of NOAC</intervention_name>
    <description>Initiation of NOAC up until day 4 after acute ischemic stroke in patients with atrial fibrillation</description>
    <arm_group_label>Early start of NOAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Late start of NOAC</intervention_name>
    <description>Initiation of NOAC between day 5 and day 10 after acute ischemic stroke in patients with atrial fibrillation</description>
    <arm_group_label>Late start of NOAC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (≥ 18 years) with acute ischemic stroke and atrial fibrillation&#xD;
&#xD;
          -  Eligible and willing to start (or re-start) NOAC&#xD;
&#xD;
          -  Registered in The Swedish Stroke Register&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindication to NOAC (e.g. ongoing bleeding, mechanical heart valve prosthesis)&#xD;
&#xD;
          -  Ongoing therapy with NOAC (without ≥2 days interruption at index stroke)&#xD;
&#xD;
          -  International normalized ratio (INR)&gt;1.7&#xD;
&#xD;
          -  No second brain imaging (CT/MRI) after thrombolysis/thrombectomy&#xD;
&#xD;
          -  Previous randomization in the TIMING study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonas Oldgren, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Medical Sciences, Uppsala University, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Signild Åsberg, MD. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Medical Sciences, Uppsala University, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alingås Hospital</name>
      <address>
        <city>Alingsås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Enköping Hospital</name>
      <address>
        <city>Enköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mälarsjukhuset Hospital</name>
      <address>
        <city>Eskilstuna</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Falu Hospital</name>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gävle Hospital</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital Östra</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallands Hospital</name>
      <address>
        <city>Halmstad</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsingborg Hospital</name>
      <address>
        <city>Helsingborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital - Huddinge</name>
      <address>
        <city>Huddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudiksvalls sjukhus</name>
      <address>
        <city>Hudiksvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hässleholm Hospital</name>
      <address>
        <city>Hässleholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ryhov</name>
      <address>
        <city>Jönköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kalmar Hopsital</name>
      <address>
        <city>Kalmar</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Länssjukhuset Kalmar</name>
      <address>
        <city>Kalmar</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kiruna Hospital</name>
      <address>
        <city>Kiruna</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kungälv Hospital</name>
      <address>
        <city>Kungälv</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Köping Hospital</name>
      <address>
        <city>Köping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lindesberg Hospital</name>
      <address>
        <city>Lindesberg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malmö University Hospital</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Motala Hospital</name>
      <address>
        <city>Motala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset Mölndal</name>
      <address>
        <city>Mölndal</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nyköping Hospital</name>
      <address>
        <city>Nyköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oskarshamn Hospital</name>
      <address>
        <city>Oskarshamn</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skaraborg Hospital</name>
      <address>
        <city>Skövde</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Solna</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capio S:t Görans Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danderyd University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sundsvall County Hospital</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Umeå</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallands Hospital</name>
      <address>
        <city>Varberg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Västerås Hospital</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 8, 2016</study_first_submitted>
  <study_first_submitted_qc>November 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2016</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral anticoagulants (NOAC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

